Results 161 to 170 of about 9,340 (184)

Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.

Rhinology
BACKGROUND Loss of smell is one of the most bothersome and difficult-to-treat symptoms in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
J. Mullol, V. Lund, M. Wagenmann, Joseph K. Han, Ana R. Sousa, Steven G. Smith, B. Mayer, R. Chan, W. Fokkens   +8 more
semanticscholar   +1 more source

Mepolizumab

Reactions Weekly, 2021
  +5 more sources

Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study

Frontiers in Immunology
Background Mepolizumab (MPZ) has demonstrated efficacy in clinical trials for eosinophilic granulomatosis with polyangiitis (EGPA); however, few studies compare the disease course between patients treated with MPZ (MPZ group) and those who were not ...
Mayu Shiomi, R. Watanabe, S. Matsuda, Takuya Kotani, Ayana Okazaki, Y. Masuda, Tsuneyasu Yoshida, Mikihito Shoji, R. Tsuge, K. Kadoba, R. Hiwa, W. Yamamoto, Akitoshi Takeda, Yoshiaki Itoh, M. Hashimoto   +14 more
semanticscholar   +1 more source

Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care.

American Journal of Otolaryngology
BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation. Mepolizumab was approved for the treatment of CRSwNP in 2021, it may be useful to evaluate its safety profile in a real-world setting ...
C. Galletti, Francesco Ciodaro, Maria Antonietta Barbieri, Fabiana Gambino, Mariagrazia Ferrisi, D. Portelli, N. Catalano, Edoardo Spina, F. Freni, Bruno Galletti   +9 more
semanticscholar   +1 more source

Comparative Effectiveness of Mepolizumab, Benralizumab and Dupilumab among Patients with Difficult-to-Control Asthma.

Annals of the American Thoracic Society
Rationale The comparative effectiveness of biologics used as add-on therapy in the management of difficult-to-control asthma is unclear. Objective To compare the effectiveness of dupilumab, mepolizumab and benralizumab among patients with difficult-to ...
C. Kearney, Ruchika Sangani, D. Shankar, George T O'Connor, A. Law, A. Walkey, N. Bosch   +6 more
semanticscholar   +1 more source

Real-world effectiveness of dupilumab versus benralizumab and mepolizumab.

Allergy and Asthma Proceedings
INTRODUCTION In the United States, this real-world study compared the effectiveness of dupilumab, benralizumab, andmepolizumab in reducing exacerbations and systemic corticosteroid (SCS) prescriptions among patients with asthma.
E. Bleecker, M. Blaiss, J. Jacob-Nara, L. Huynh, Tracy Guo, M. Ye, R. Stanford, Zhixiao Wang, X. Soler, Arpita Nag, Radhika Nair, K. Borsos   +11 more
semanticscholar   +1 more source

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study

Lancet Respiratory Medicine,the, 2021
P Jane Mcdowell, John Busby, Rahul Shrimanker   +2 more
exaly  

Mepolizumab

Reactions Weekly, 2010
openaire   +1 more source

Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial

Lancet, The, 2022
exaly  

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

Lancet, The, 2012
Ian D Pavord, Peter Howarth, Oliver N Keene   +2 more
exaly